How Does Regeneron Pharmaceuticals Stock Stack Up Against Its Peers?
Regeneron stock has underperformed peers over the past year, but how does it truly stack up against biotech rivals like Amgen and Gilead? A closer look reveals strong profitability and an attractive valuation (PE 12.7), yet slower revenue growth (2.9%) compared to peers might limit its upside if competitors’ pipelines deliver sustained outperformance. Analysis as of 12/3/2025.
- REGN’s 26.7% operating margin is robust, yet GILD’s 38.3% reflects superior cost discipline and high-margin product mix.
- REGN’s 2.9% revenue growth is modest due to EYLEA competition; peers AMGN, BIIB, JAZZ, BMRN saw stronger gains from new launches. GILD lags.
- REGN’s -2.9% stock decline reflects competitive pressure on EYLEA. Its 12.7 PE ratio, below industry average, may signal undervaluation.
Here’s how Regeneron Pharmaceuticals stacks up across size, valuation, and profitability versus key peers.
| REGN | AMGN | GILD | BIIB | JAZZ | BMRN | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 75.0 | 185.8 | 155.4 | 26.5 | 10.1 | 10.4 |
| Revenue ($ Bil) | 14.2 | 36.0 | 29.1 | 10.1 | 4.2 | 3.1 |
| PE Ratio | 12.7 | 21.7 | 17.0 | 12.8 | -21.7 | 20.0 |
| LTM Revenue Growth | 2.9% | 10.6% | 2.8% | 4.8% | 4.1% | 12.4% |
| LTM Operating Margin | 26.7% | 24.1% | 38.3% | 24.8% | 10.9% | 19.9% |
| LTM FCF Margin | 27.2% | 32.1% | 31.5% | 22.5% | 29.8% | 26.7% |
| 12M Market Return | -2.9% | 28.1% | 39.2% | 12.4% | 37.4% | -14.1% |
For more details on Regeneron Pharmaceuticals, read Buy or Sell REGN Stock. Below we compare REGN’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| REGN | 2.9% | 8.3% | 7.8% | -24.3% |
| AMGN | 10.6% | 18.6% | 7.1% | 1.3% |
| GILD | 2.8% | 6.0% | -0.6% | -0.1% |
| BIIB | 4.8% | -1.6% | -3.3% | -7.4% |
| JAZZ | 4.1% | 6.1% | 4.8% | 18.3% |
| BMRN | 12.4% | 18.0% | 15.4% | 13.5% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| REGN | 26.7% | 28.8% | 32.3% | 41.0% |
| AMGN | 24.1% | 21.7% | 28.0% | 36.3% |
| GILD | 38.3% | 36.5% | 32.5% | 40.2% |
| BIIB | 24.8% | 22.9% | 18.6% | 28.5% |
| JAZZ | 10.9% | 17.9% | 15.6% | 14.0% |
| BMRN | 19.9% | 16.6% | 7.7% | 2.7% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| REGN | 12.7 | 17.4 | 23.7 | 17.8 |
| AMGN | 21.7 | 34.2 | 22.9 | 21.6 |
| GILD | 17.0 | 240.0 | 17.8 | 23.5 |
| BIIB | 12.8 | 13.6 | 32.2 | 13.2 |
| JAZZ | -21.7 | 13.6 | 18.8 | -44.5 |
| BMRN | 20.0 | 29.3 | 108.0 | 135.4 |
Still not sure about REGN stock? Consider portfolio approach.
Multi Asset Portfolios Offer More Upside With Less Risk
Single markets are unpredictable but different assets react differently. A multi asset portfolio cuts downside shocks while keeping upside on the table.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices